Based on these studies, ivosidenib gained FDA approval as a monotherapy for patients with IDH1 mutation in r/r AML or elderly patients ≥75 years or not suitable for intensive induction chemotherapy in 2018 and 2019, respectively. Here, IDH1 is linked to acute myeloid leukemia.